摘要
目的评价小剂量索他洛尔治疗阵发性心房颤动的疗效及安全性。方法收集阵发性房颤患者24例,口服索他洛尔40～80～120mg/d,分2次口服,每2d递加,2周后做24h心电图观察早Q-T、阵发性房颤发作减少的百分率、Q-T间期及24h平均心率并判定疗效。结果24例阵发性房颤中,有效14例,无效10例,总有效率为58.3%;治疗后24h平均心率(次/min)较前明显降低[(80.2±6.8)vs(65.8±8.4),P<0.01)];治疗后Q-T间期(s)较前明显延长[(0.38±0.02)vs(0.40±0.02),P<0.01]。结论小剂量索他洛尔预防阵发性房颤的复发和减少发作次数有较好的疗效。
Objective To evaluate the safety and efficacy of oral sotalol treatment for symptomatic paroxysmal atrial fibrillation(PAF). Methods There were 24 patients with PAF. Sotalol was given at dosage 20 mg per 12 h and then increased 20 mg per 2 days. After 2 weeks,the patients were evaluated by 24 h ambulatory Holter. Results All patients had completed the trial. The effective rate was 58.3%. The 24 h average heat rate was decreased from (80.2±6.8)beats/minute at baseline to (65.8±8.4) beats/minute after treatment(P<0.01). Q-T interval was prolonged from( 0.38±0.02) s at baseline to (0.40±0.02) s after treatment(P<0.01). Conclusion Sotalol is effective in decreasing the attack frequency of symptomatic paroxysmal atrial fibrillation. When it is used at 120 mg/d, a little side effect is found, sotalol is an effective and safe antiarrhythmic drug.
出处
《山西医科大学学报》
CAS
2005年第2期197-199,共3页
Journal of Shanxi Medical University
关键词
心房颤动
索他洛尔
治疗结果
atrial fibrillation
sotalol
treatment outcome
